Galapagos spotlights an 'exciting' round of PoC data for IPF drug, shares surge
Galapagos $GLPG says it got the proof-of-concept data researchers were looking for from their mid-stage trial of GLPG1690 for idiopathic pulmonary fibrosis and will now push forward as planned into a pivotal program.
Fast on the heels of a riotous reception for FibroGen’s PoC round for a rival IPF drug, the Belgian biotech says their drug clearly stabilized a small group of patients with the disease while patients in the placebo arm continued to decline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.